Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Toxicology in Vitro

• Publication date

  2018-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.tiv.2017.12.001PMID 29223572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

  2017cited by this paper
• Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies

  2017cited by this paper
• Molecular targets of curcumin for cancer therapy: an updated review

  2016cited by this paper
• NF-κB dysregulation in multiple myeloma.

  2016cited by this paper
• Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

  2016cited by this paper
• Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis

  2016cited by this paper
• Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting

  2015cited by this paper
• Palmitate-induced endothelial dysfunction is attenuated by cyanidin-3-O-glucoside through modulation of Nrf2/Bach1 and NF-κB pathways.

  2015cited by this paper
• Overcoming bortezomib resistance in multiple myeloma.

  2014cited by this paper
• Molecularly Targeted Therapies in Multiple Myeloma

  2014cited by this paper
• Apoptosis and Molecular Targeting Therapy in Cancer

  2014cited by this paper
• Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma

  2014cited by this paper
• Cytotoxic effects induced in vitro by organic extracts from urban air particulate matter in human leukocytes

  2014cited by this paper
• New Approaches to Management of Multiple Myeloma

  2014cited by this paper
• Old, new and emerging functions of caspases

  2014cited by this paper
• Proteasome inhibitors in the treatment of multiple myeloma

  2013cited by this paper
• Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

  2013cited by this paper
• Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

  2013cited by this paper
• p21WAF1 and tumourigenesis: 20 years after

  2013cited by this paper
• Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

  2012cited by this paper
• Relationship Between Advanced Oxidation Protein Products, Advanced Glycation End Products, and S-Nitrosylated Proteins With Biological Risk and MDR-1 Polymorphisms in Patients Affected by B-Chronic Lymphocytic Leukemia

  2012cited by this paper
• Curcumin Enhances Cytotoxic Effects of Bortezomib in Human Multiple Myeloma H929 Cells: Potential Roles of NF-κB/JNK

  2012cited by this paper
• Manipulation of cellular redox parameters for improving therapeutic responses in B‐cell lymphoma and multiple myeloma

  2012cited by this paper
• Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs

  2011cited by this paper
• Multiple myeloma.

  2011cited by this paper
• Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.

  2010cited by this paper
• Bryostatin 1 activated PKD1 and β-catenin signaling

  2009cited by this paper
• Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model

  2009cited by this paper
• p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint.

  2008cited by this paper
• Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells

  2008cited by this paper
• Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

  2008cited by this paper
• Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

  2008cited by this paper
• Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.

  2008cited by this paper
• New therapies in multiple myeloma

  2007cited by this paper
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

  2007cited by this paper
• NF-κB: linking inflammation and immunity to cancer development and progression

  2005cited by this paper
• NF-kappaB: linking inflammation and immunity to cancer development and progression.

  2005cited by this paper
• Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

  2005cited by this paper
• Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.

  2004cited by this paper
• Curcumin (Diferuloylmethane) Inhibits Receptor Activator of NF-κB Ligand-Induced NF-κB Activation in Osteoclast Precursors and Suppresses Osteoclastogenesis1

  2004cited by this paper
• Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

  2003cited by this paper
• Anticancer potential of curcumin: preclinical and clinical studies.

  2003cited by this paper
• NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach.

  2003cited by this paper
• Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications

  2003cited by this paper
• p21 is necessary for the p53-mediated G1 arrest in human cancer cells.

  1995cited by this paper
• The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA

  1994cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.

  1970cited by this paper
• Nuclear factor– (cid:1) B and STAT3 are constitutively active in CD138 (cid:2) cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

  year unknowncited by this paper

• Mechanistic and translational insights into plant-derived natural products in preclinical multiple myeloma research: Current evidence

  2026cites this paper
• Combination effects of Pistachio hull and carfilzomib on NF-κB p65, MDR1, MRP1, and Caspase3 gene expression in breast cancer cell line

  2025cites this paper
• Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers

  2025cites this paper
• Photodynamic Therapy and Dietary Antioxidants: A Dual Strategy for Genome Stability and DNA Damage Repair

  2025cites this paper
• Effects of curcumin-loaded amine-functionalized mesoporous silica nanoparticles on apoptosis induction and cell cycle arrest in RPMI-8226 multiple myeloma cell line

  2025cites this paper
• Curcumin in treatment of hematological cancers: Promises and challenges

  2024cites this paper
• Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors

  2024cites this paper
• Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

  2024cites this paper
• Conceptualizing an Integrative Multiple Myeloma Care: The Role of Nutrition, Supplements, and Complementary Modalities

  2024cites this paper
• Low concentrations of antimony impair adipogenesis and endoplasmic reticulum homeostasis during 3T3-L1 cells differentiation.

  2023cites this paper
• A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models

  2023cites this paper
• The effect of environmental stressors on the anticancer potential of Amaranthus hypochondriacus aqueous extracts and fractions

  2023cites this paper
• Regulation of mitotic clonal expansion and thermogenic pathway are involved in the antiadipogenic effects of cyanidin-3-O-glucoside

  2023cites this paper
• Gender Differences in Oxidative Stress in Relation to Cancer Susceptibility and Survival

  2023cites this paper
• Modulation of the ubiquitin‐proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors

  2023cites this paper
• Effect of Diet and Oxidative Stress in the Pathogenesis of Lymphoproliferative Disorders

  2023cites this paper
• Targeted Alpha Therapy of Glioma Using 211At-Labeled Heterodimeric Peptide Targeting Both VEGFR and Integrins.

  2022cites this paper
• Critical Role of Aquaporins in Cancer: Focus on Hematological Malignancies

  2022cites this paper
• Specialized Intercellular Communications via Tunnelling Nanotubes in Acute and Chronic Leukemia

  2022cites this paper
• Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma

  2022cites this paper
• Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma

  2022cites this paper
• Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies

  2022cites this paper
• Natural products and oxidative stress: potential agents against multiple myeloma

  2022cites this paper
• Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma

  2022cites this paper
• New Insights into Cold Shock Proteins Effects in Human Cancer: Correlation with Susceptibility, Prognosis and Therapeutical Perspectives.

  2022cites this paper
• The Impact of Curcumin on Immune Response: An Immunomodulatory Strategy to Treat Sepsis

  2022cites this paper
• Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies

  2022cites this paper
• Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions

  2022cites this paper
• Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

  2021cites this paper
• Ubiquitination in the regulation of inflammatory cell death and cancer

  2021cites this paper
• Molecular targets for the management of cancer using Curcuma longa Linn. phytoconstituents: A Review.

  2021cites this paper
• The Mechanism of the Synergistic Anticancer Effect of CDDP and EPA in the TE1 Cell Line

  2021cites this paper
• Preliminary in vitro comparison of 111In and 131I labeled nimotuzumabs

  2021cites this paper
• Preliminary in vitro comparison of 111 In and

  2021cites this paper
• New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges

  2021cites this paper
• SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma

  2021cites this paper
• Role of Dietary Antioxidants in p53-Mediated Cancer Chemoprevention and Tumor Suppression

  2021cites this paper
• Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial

  2021cites this paper
• New insights into neuropeptides regulation of immune system and hemopoiesis: effects on hematologic malignancies.

  2021cites this paper
• Functional drug–target–disease network analysis of gene–phenotype connectivity for curcumin in hepatocellular carcinoma

  2021cites this paper
• Curcumin encapsulation in functional PLGA nanoparticles: A promising strategy for cancer therapies.

  2021cites this paper
• Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy

  2020cites this paper
• Antiproliferative Effects of St. John’s Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies

  2020cites this paper
• The Osteoporosis/Microbiota Linkage: The Role of miRNA

  2020cites this paper
• Drug repositioning for the treatment of hematologic disease: limits, challenges and future perspectives.

  2020cites this paper
• Functional drug–target–disease network analysis of gene–phenotype connectivity for curcumin in cancer

  2020cites this paper
• Vitamin deficiency as risk factor for SARS-CoV-2 infection: correlation with susceptibility and prognosis.

  2020cites this paper
• Anti-Cancer Activity of Curcumin on Multiple Myeloma.

  2020cites this paper
• The Role of the Curcumin for Inducing Apoptosis in Acute Lymphoblastic Leukemia Cells: A Systematic Review

  2020cites this paper
• Anticancer Activity of Rosmarinus officinalis L.: Mechanisms of Action and Therapeutic Potentials

  2020cites this paper
• Application of curcumin and its derivatives in tumor multidrug resistance

  2020cites this paper
• Relationship between mitofusin 2 and cancer.

  2019cites this paper
• The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.

  2019cites this paper
• Curcumin and Cancer

  2019cites this paper
• Targeting multiple myeloma with natural polyphenols.

  2019cites this paper
• Effect of one and five-day curcumin consumption on muscle damage indices after an eccentric exercise session in untrained young men

  2019cites this paper
• Curcumin potentiates the antitumor activity of Paclitaxel in rat glioma C6 cells.

  2019cites this paper
• Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation.

  2018cites this paper
• Review on Discovery and Development of Novel Phytochemicals which can be used in Functional Foods

  2018cites this paper
• Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2

  2018cites this paper
• Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense

  2018cites this paper